Published: Jan. 1, 2024
Language: Английский
Biotechnology and Applied Biochemistry, Journal Year: 2025, Volume and Issue: unknown
Published: Feb. 21, 2025
ABSTRACT As a significant cause of global mortality, the cancer has also economic impacts. In era therapy, mitigating side effects and costs overcoming drug resistance is crucial. Microbial species can grow inside tumor microenvironment inhibit growth through direct killing cells immunoregulatory effects. Although microbiota or their products have demonstrated anticancer effects, possibility acting as pathogens exerting in certain individuals risk. Hence, several genetically modified/engineered bacteria (GEB) been developed to this aim with ability diagnosing selective targeting destruction cancers. Additionally, GEB are expected be considerably more efficient, safer, permeable, less costly, invasive theranostic approaches compared wild types. Potential strains such Escherichia coli (Nissle 1917, MG1655), Salmonella typhimurium YB1 SL7207 ( aroA gene deletion), VNP20009 (∆msbB/∆purI) ΔppGpp (P Tet P BAD ), Listeria monocytogenes Lm at ‐LLO combat cells. When used tandem conventional treatments, substantially improve efficacy therapy outcomes. addition, public acceptance, optimal timing (s), duration dose identification, interactions other host cells, efficacy, safety quality, potential risks ethical dilemmas include major challenges.
Language: Английский
Citations
2
Cell Insight, Journal Year: 2025, Volume and Issue: unknown, P. 100227 - 100227
Published: Jan. 1, 2025
The human gut microbiota plays a critical role in maintaining host homeostasis through metabolic activities. Among these, amino acid (AA) metabolism by the large intestine is highly heterogeneous and relevant to health. Despite increasing interest, microbial AA remains relatively unexplored. This review highlights recent advances colonic metabolism, including auxotrophies, synthesis, dissimilatory metabolites, their implications health, focusing on major gastrointestinal diseases colorectal cancer, inflammatory bowel disease, irritable syndrome.
Language: Английский
Citations
1
Molecules, Journal Year: 2024, Volume and Issue: 29(11), P. 2431 - 2431
Published: May 21, 2024
An increased demand for natural products nowadays most specifically probiotics (PROs) is evident since it comes in conjunction with beneficial health effects consumers. In this regard, well known that encapsulation could positively affect the PROs' viability throughout food manufacturing and long-term storage. This paper aims to analyze review various double/multilayer strategies of PROs. Double-layer PROs by electrohydrodynamic atomization or electrospraying technology has been reported along layer-by-layer assembly water-in-oil-in-water (W
Language: Английский
Citations
4
Biosensors, Journal Year: 2025, Volume and Issue: 15(3), P. 188 - 188
Published: March 14, 2025
This study provides a comprehensive analysis of the complex interaction between heavy metals (HMs) and gut microbiota, adopting bidirectional approach that explores both influence HMs on microbiota populations potential role probiotics in modulating these changes. By examining interconnected aspects, aims to offer deeper understanding how disrupt microbial balance probiotic interventions may mitigate or reverse effects, promoting detoxification processes overall health. In addition, review highlights innovative tools, such as biosensors, for rapid, precise, non-invasive detection urine. These advanced technologies enable real-time monitoring effectiveness probiotic-based interventions, offering critical insights into their elimination from body improving detoxification.
Language: Английский
Citations
0
Molecular Nutrition & Food Research, Journal Year: 2025, Volume and Issue: unknown
Published: March 20, 2025
ABSTRACT Colorectal cancer (CRC) is the third leading cause of cancer‐related mortality globally and presents significant challenges in treatment patient care. Capecitabine, a widely used prodrug 5‐fluorouracil (5‐FU), offers targeted delivery with reduced systemic toxicity compared to traditional chemotherapies. However, capacitabine associated adverse effects, such as hand‐foot syndrome, gastrointestinal issues, mucositis. Emerging evidence suggests that probiotics, particularly Bifidobacterium, play pivotal role gut microbiota modulation, promoting anti‐inflammatory cytokines short‐chain fatty acids, butyrate, which possess both intestinal protective anti‐cancer properties. In this review, we explored potential Bifidobacterium improve chemotherapy outcomes by mitigating inflammation enhancing mucosal immunity CRC patients. Furthermore, demonstrated silico approaches, including molecular docking protein–protein interaction analysis, for Toll‐like receptor 2 (TLR‐2), key mediator immunity. Docking results revealed strong binding affinity, suggesting activation pathways. Notably, enhanced IL‐10 production while reducing pro‐inflammatory cytokines, IL‐6 TNF‐α, fostering homeostasis chronic inflammation, driver progression. Therefore, future research should focus on personalized probiotics validating their synergy immunotherapy outcomes.
Language: Английский
Citations
0
European Journal of Pharmacology, Journal Year: 2025, Volume and Issue: unknown, P. 177590 - 177590
Published: April 1, 2025
Language: Английский
Citations
0
Pharmacological Research, Journal Year: 2025, Volume and Issue: 215, P. 107726 - 107726
Published: April 4, 2025
Triple-negative breast cancer (TNBC) is an aggressive subtype of with limited treatment options and poor prognosis. The gut microbiota, a diverse community microorganisms in the gastrointestinal tract, plays crucial role regulating immune responses through gut-immune axis. Recent studies have highlighted its significant impact on TNBC progression efficacy immunotherapies. This review examines interactions between microbiota system TNBC, focusing key cells pathways involved tumor immunity. It also explores modulation strategies, including probiotics, prebiotics, dietary interventions, fecal transplantation, as potential methods to enhance immunotherapeutic outcomes. Understanding these mechanisms offers promising avenues for improving patient prognosis TNBC.
Language: Английский
Citations
0
BMC Gastroenterology, Journal Year: 2025, Volume and Issue: 25(1)
Published: May 16, 2025
Colorectal cancer (CRC) is a common malignant tumor. Immune checkpoint inhibitors (ICIs), particularly those targeting programmed cell death protein 1(PD-1) and ligand 1(PD-L1), have shown promising potential in the treatment of CRC. Specific gut microbiota can modulate efficacy ICIs through immune or metabolic pathways. This review summarizes recent advances combined application PD-1/PD-L1 CRC, aiming to provide insights for expanding clinical options We employed systematic search strategy screen relevant literature from databases such as PubMed, EMBASE, Medline, Cochrane Library, Clinical Trial registries, with period covering inception each database October 2024. study includes animal models human trial subjects. Data extraction screening were strictly carried out by two independent researchers. A total 8 studies 5 trials included evaluate effects Tumor types Microsatellite Stability(MSS), Instability-Low(MSI-L), MSI-H Main outcomes tumor volume, weight, incidence; one reported survival. Study durations ranged 20 days 26 weeks. Two used fecal transplantation(FMT), six applied experimental microbial interventions. The ORR primary endpoint.Some also DCR, PFS, OS. targeted Instability-High(MSI-H)/Deficient Mismatch Repair(dMMR), MSS/Proficient Repair(pMMR), lacked molecular subtype specification. All full transplantation; has released preliminary data. regimen combining therapeutic prospects both research, although most are data remain limited. Future should focus on: (1) gene-edited probiotic strains modifications; (2) synergistic multiple probiotics; (3) conducting high-quality, multicenter trials.
Language: Английский
Citations
0
Published: Jan. 1, 2024
Language: Английский
Citations
0